Founded by leading experts in microbial research and drug discovery, Second Genome is building a proprietary, first-in-class microbiome drug discovery and development platform to develop novel therapeutics in a range of diseases.

By bringing microbiome science to the discovery and development of therapeutic products, Second Genome has established a development pipeline fueled by novel technologies for identifying, screening, and scientifically validating product candidates. Our science is based on a comprehensive understanding of host-microbe interactions and the resulting implications in driving disease.

Founded on groundbreaking science from Lawrence Berkeley National Laboratory with the support of veteran biotechnology entrepreneurs, our technologies have been validated through partnerships with Janssen, Bayer, and others. We are backed by investors with a track record of value creation, including Pfizer Venture Investments, Roche Venture Fund, SR One Venture Partners, and Digitalis Ventures.